A NanoStat™ for MRSA Nasal Carriage:

This product is an antibiotic free nasally applied prophylactic treatment effective against resistant and non-resistant S. aureus that is in preclinical development stages at NanoBio.  Because of its unique mechanism of action, has minimal potential for creating resistant strains.

Based on the inherent safety and lack of resistance issues, this NanoStat could be administered to all individuals exposed to a high risk situation such as a hospital visit.  In preclinical studies the product has demonstrated efficacy in vitro against MRSA and VRSA at dosages that are 500 fold lower concentrations than the maximal safe dose for nasal application.  It is expected that this product will also be proven effective as a topical treatment for active dermal staphylococcus infections. 

About MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that is resistant to certain antibiotics.  Staphylococcus aureus (S. aureus) infections, including MRSA, occur most frequently among persons in hospitals, gymnasiums and healthcare facilities.  The symptoms can range from skin boils to necrotizing faciitis, popularly known as flesh-eating disease.  MRSA infections are typically combated with vancomycin, however, incidences of vancomycin-resistant staphylococcus (VRSA) are increasing rapidly. 

According to the U.S. Centers for Disease Control more that 2 million patients in the U.S. each year contract a S. aureus infection as a result of receiving healthcare in a hospital.  Up to 53 million people in the US are thought to carry MRSA. 

S. aureus most commonly colonizes the anterior nares (the nostrils) although the respiratory tract, open wounds, intravenous catheters and the urinary tract are also potential sites for infection.  Currently S. aureus infections are treated via the use of systemic antibiotics.  Individuals who are known carriers of S. aureus can treat prophylactically via the use of the nasally applied antibiotic, mupirocin (Bactroban®).